Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions.
BA.2
COVID-19
Delta
Omicron BA.1
SARS-CoV-2
viruses
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 May 2022
16 May 2022
Historique:
received:
25
03
2022
revised:
04
05
2022
accepted:
10
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
BA.2, a sublineage of Omicron BA.1, is now prominent in many parts of the world. Early reports have indicated that BA.2 is more infectious than BA.1. To gain insight into BA.2 mutation profile and the resulting impact of mutations on interactions with receptor and/or monoclonal antibodies, we analyzed available sequences, structures of Spike/receptor and Spike/antibody complexes, and conducted molecular dynamics simulations. The results showed that BA.2 had 50 high-prevalent mutations, compared to 48 in BA.1. Additionally, 17 BA.1 mutations were not present in BA.2. Instead, BA.2 had 19 unique mutations and a signature Delta variant mutation (G142D). The BA.2 had 28 signature mutations in Spike, compared to 30 in BA.1. This was due to two revertant mutations, S446G and S496G, in the receptor-binding domain (RBD), making BA.2 somewhat similar to Wuhan-Hu-1 (WT), which had G446 and G496. The molecular dynamics simulations showed that the RBD consisting of G446/G496 was more stable than S446/S496 containing RBD. Thus, our analyses suggested that BA.2 evolved with novel mutations (i) to maintain receptor binding similar to WT, (ii) evade the antibody binding greater than BA.1, and (iii) acquire mutation of the Delta variant that may be associated with the high infectivity.
Identifiants
pubmed: 35628343
pii: ijms23105534
doi: 10.3390/ijms23105534
pmc: PMC9141577
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institute of Allergy and Infectious Diseases
ID : R01 AI129745, R01 AI113883
Organisme : NIDA NIH HHS
ID : R01 DA052845
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI129745
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI113883
Pays : United States
Organisme : University of Missouri, Bond Life Sciences Center,
ID : ECG
Organisme : NIAID NIH HHS
ID : R21 AI144374
Pays : United States
Références
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
Protein Cell. 2022 Sep;13(9):689-693
pubmed: 34687004
Science. 2022 Feb 18;375(6582):760-764
pubmed: 35050643
J Autoimmun. 2021 Nov;124:102715
pubmed: 34399188
PLoS Pathog. 2022 Feb 17;18(2):e1010260
pubmed: 35176090
Nature. 2021 Dec;600(7889):512-516
pubmed: 34544114
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Nature. 2022 Feb;602(7896):300-306
pubmed: 34823256
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
N Engl J Med. 2022 Apr 14;386(15):1477-1479
pubmed: 35263515
Cell. 2021 Jun 24;184(13):3474-3485.e11
pubmed: 34143953
Bioinformatics. 2011 Jul 15;27(14):2001-2
pubmed: 21593132
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
BMJ. 2022 Feb 11;376:o358
pubmed: 35149516
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
Science. 2022 Feb 25;375(6583):864-868
pubmed: 35076256
JAMA. 2021 Aug 13;:
pubmed: 34387645
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
J Autoimmun. 2022 Jan;126:102779
pubmed: 34915422